不同种族和族裔人群梅克尔细胞癌表现与结局的差异
该回顾性队列研究纳入2000年至2018年美国国家癌症研究所监测、流行病学和最终结果项目18个人群癌症登记处诊断并随访的9557例梅克尔细胞癌患者,分析种族和族裔与疾病表现及特异性生存的关系。西班牙裔患者较白人患者的梅克尔细胞癌特异性生存改善(HR 0.82,95%CI 0.67-0.99,P=0.04),黑人患者特异性生存最低但与白人患者无统计学差异(HR 1.19,95%CI 0.86-1.60,P=0.28)。
要点
- 西班牙裔梅克尔细胞癌患者较白人患者特异性生存改善(HR 0.82,95%CI 0.67-0.99,P=0.04)。
- 黑人患者特异性生存最低,但与白人患者无统计学差异(HR 1.19,95%CI 0.86-1.60,P=0.28)。
- 黑人患者较白人患者更常诊断时即为晚期(40.4% vs 29.2%,P=0.004)。
核心结论
- 在该队列研究中,不同种族和族裔群体间观察到的梅克尔细胞癌结局和疾病特征存在差异。
- 与白人患者相比,西班牙裔梅克尔细胞癌患者结局改善,黑人患者尽管诊断时分期更晚但结局并未更差,这些发现需进一步研究。
研究设计与样本
- 回顾性队列研究,纳入2000年至2018年美国国家癌症研究所监测、流行病学和最终结果项目18个人群癌症登记处诊断并随访的梅克尔细胞癌患者。
- 排除无随访数据的患者,共纳入9557例患者(6758例[70.7%]年龄≥70岁;6008例[62.9%]男性)。
- 数据分析时间为2022年3月12日至2022年11月30日。
主要发现
- 9557例患者中,222例(2.3%)为亚裔美国人或太平洋岛民,146例(1.5%)为黑人,541例(5.7%)为西班牙裔,8590例(89.9%)为白人。
- 西班牙裔患者较白人患者梅克尔细胞癌特异性生存改善(HR 0.82,95%CI 0.67-0.99,P=0.04)。
- 黑人患者梅克尔细胞癌特异性生存最低,但与白人患者无统计学差异(HR 1.19,95%CI 0.86-1.60,P=0.28)。
- 西班牙裔和黑人患者较白人患者原发部位为头颈部的比例更低(西班牙裔183/541[33.8%]和黑人45/146[30.8%] vs 白人3736/8590[43.5%];P<0.001和P=0.002)。
- 黑人患者较白人患者诊断时晚期疾病比例更高(59/146[40.4%] vs 2510/8590[29.2%];P=0.004)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Racial and ethnic differences in skin cancer outcomes are understudied. Delineating these differences in Merkel cell carcinoma (MCC) is needed to better understand this rare disease. OBJECTIVE: To determine how MCC presentation and outcomes differ across racial and ethnic groups. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients diagnosed with MCC and followed up from 2000 through 2018 in the 18 population-based cancer registries of the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. Patients without follow-up data were excluded. Data analysis occurred from March 12 to November 30, 2022. MAIN OUTCOMES AND MEASURES: A Cox proportional hazards regression was conducted to determine associations between demographic variables (race and ethnicity, age, sex, and income) and clinical variables (stage at diagnosis, primary site, and diagnosis year) with MCC-specific survival. RESULTS: Of the 9557 patients with MCC identified (6758 [70.7%] aged ≥70 years; 6008 [62.9%] male), 222 (2.3%) were Asian American or Pacific Islander, 146 (1.5%) Black, 541 (5.7%) Hispanic, and 8590 (89.9%) White. Hispanic patients had improved MCC-specific survival compared with White patients (hazard ratio, 0.82; 95% CI, 0.67-0.99; P = .04). Black patients had the lowest MCC-specific survival, but it was not statistically different from White patients (hazard ratio, 1.19; 95% CI, 0.86-1.60; P = .28). Hispanic and Black patients were less likely to present with a primary site of the head and neck than White patients (183 of 541 [33.8%] Hispanic patients and 45 of 146 [30.8%] Black patients vs 3736 of 8590 [43.5%] White patients; P < .001 and P = .002, respectively). Black patients presented more often than White patients with advanced disease at diagnosis (59 of 146 [40.4%] vs 2510 of 8590 [29.2%]; P = .004). CONCLUSIONS AND RELEVANCE: In this cohort study, there were differences between racial and ethnic groups in observed MCC outcomes and disease characteristics. Further investigations are warranted into the findings that, compared with White patients, Hispanic patients with MCC had improved outcomes and Black patients did not have worse outcomes despite presenting with more advanced disease.
引用
- Mohsin N, Martin MR, Reed DJ, et al. Differences in Merkel Cell Carcinoma Presentation and Outcomes Among Racial and Ethnic Groups. JAMA Dermatol. 2023. PMID: 36920369. doi:10.1001/jamadermatol.2023.0061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。